What's Going On With MedTech Focused Inogen Stock On Wednesday?
1. Inogen reported Q4 adjusted EPS loss of 24 cents, beating consensus by 37 cents. 2. Sales for Q4 reached $80.1 million, exceeding $73.9 million consensus. 3. Total revenue grew 5.5% year-over-year, driven by B2B sales growth. 4. Company expects Q1 2025 sales guidance of $79-$81 million, above consensus. 5. Despite challenges, strategical shifts position Inogen for future growth.